# Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma

> **NCT01680796** · PHASE1 · WITHDRAWN · sponsor: **University of Florida**

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Dovitinib
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01680796
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-02
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The target drug, dovitinib, failed as a single agent in prior studies in patients with heavily treated multiple myeloma.
- **Last updated:** 2013-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01680796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01680796, "Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01680796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*